Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
暂无分享,去创建一个
K. Budde | L. Rostaing | P. Halloran | A. Loupy | B. Jilma | G. Böhmig | M. Wahrmann | A. Kainz | F. Eskandary | H. Regele | Stefan Härtle | R. Boxhammer | C. Firbas | Konstantin Doberer | C. Schörgenhofer | Katharina A Mayer | Sarah Ely | S. Schranz | Anna Christamentl | K. Doberer